Considering options for your patients.

For patients with hemophilia A, disease management often depends on choosing a treatment that fits into their daily lives.

rFVIII Comparison Guide

as of October 24, 2017

Table: rFVIII Comparison Guide

Patients are choosing to treat with Novoeight®.

When choosing a treatment that fits into their lives, Novoeight® patientsa consider more options than just half-life.

Age 25:

Values Storage Flexibility

Hemophilia classification:
Severe hemophilia A

Bleeding pattern: 
Spontaneous bleeds, typically in ankle or knee

Joint health: 
Has minor joint damage

ABR:
1-2 joint bleeds

Current regimen: 
Prophylaxis 3 times a week

Lifestyle considerations:

  • Works at a plant nursery
  • Enjoys geology, collecting minerals and stones
  • Enjoys playing sports, especially baseball
  • Doesn’t want his factor to limit his activities whether he’s at home or on-the-go

How Novoeight® may help:
Patients who appreciate the ability to store their product without refrigeration.

Individual results may vary.

Age 34:

Values Portability

Hemophilia classification:
Severe hemophilia A

Bleeding pattern:
Spontaneous muscle/joint bleeds; rarely experiences traumatic bleeds

Joint health:
Joint damage in the right knee

ABR:
1-2 joint bleeds

Current regimen:
Prophylaxis 3 times a week

Lifestyle considerations:

  • Has 2 young daughters
  • Likes bicycling, swimming, fishing, and other outdoor pursuits
  • With treatment, he tries not to let hemophilia prevent him from living an active life
  • Needs his factor to be ready to travel

How Novoeight® may help:
Patients with a busy lifestyle.

Individual results may vary.

Age 41:

Values Reliability

Hemophilia classification:
Moderate hemophilia A

Bleeding pattern:
Sporadic epistaxis (varied severity)

Joint health:
Not many problems with joints

ABR:
3 spontaneous bleeds

Current regimen:
On-demand

Lifestyle considerations:

  • Pursues artistic hobbies
  • Has a passion for public health
  • Likes to play the keyboard and compose music
  • Travels a lot for work
  • Wants a treatment that delivers protection and is portable

How Novoeight® may help:
Patients without frequent bleeding episodes who achieve good control with a standard half-life rFVIII.

Individual results may vary.

aProfiles described are for illustrative purposes only; they are not those of actual patients.


Reliability in treating bleeds.

Shield Checkmark icon


The efficacy of Novoeight® is proven in clinical trials.9-11
 


Proven safety profile and purity.

Funnel icon


Novoeight® was shown to be safe in clinical studies.1,9,10
 


A portable treatment for your patients.

Backpack icon


Novoeight® offers storage flexibility to fit into their lives.
 

Selected Important Safety Information

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins.

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment.

Indications and Usage

Novoeight® (Antihemophilic Factor [Recombinant]) is indicated for use in adults and children with hemophilia A for control and prevention of bleeding, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

Novoeight® is not indicated for the treatment of von Willebrand disease.

Important Safety Information

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins.

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment.

Development of activity-neutralizing antibodies (inhibitors) may occur.  If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures factor VIII inhibitor concentration.

The most frequently reported adverse reactions (≥0.5%) were injection site reactions, increased hepatic enzymes, and pyrexia.

Please click here for Prescribing Information.

References

  1. Novoeight [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2016.
  2. Adynovate® [package insert]. Westlake Village, CA: Baxalta US Inc.; 2016.
  3. Advate® [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; 2015.
  4. Afstyla® [package insert]. Kankakee, IL: CSL Behring LLC; 2016.
  5. Eloctate™ [package insert]. Cambridge, MA: Biogen Idec Inc.; 2016.
  6. Kogenate® [package insert]. Tarrytown, NY: Bayer HealthCare LLC; 2014.
  7. Kovaltry® [package insert]. Whippany, NJ: Bayer HealthCare LLC; 2016.
  8. Nuwiq® [package insert]. Hoboken, NJ: Octapharma USA, Inc.; 2015.
  9. Lentz SR, Misgav M, Ozelo M, et al. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. Haemophilia. 2013; 19:691-697.
  10. Kulkarni R, Karim FA, Glamocanin S, et al. Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics. Haemophilia. 2013; 19(5):698-705.
  11. Santagostino E, Lentz SR, Misgav M, et al. Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials. Haemophilia. 2015;21(1):34-40.